GYRE – gyre therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting [Yahoo! Finance]
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
Gyre Therapeutics (NASDAQ:GYRE) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Is Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE Of 8.6% Concerning? [Yahoo! Finance]
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Form 4 GYRE THERAPEUTICS, INC. For: Jan 07 Filed by: Zhang Ping
Form 4 GYRE THERAPEUTICS, INC. For: Jan 07 Filed by: Chen Ruoyu
Form 8-K GYRE THERAPEUTICS, INC. For: Jan 05
Form 144 GYRE THERAPEUTICS, INC. Filed by: Ye Weiguo
Form 10-Q GYRE THERAPEUTICS, INC. For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.